

DOCKET NO. MUR-026

To Be A

 \overline{c}

3700 MAIL ROUM

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: K. Katagai, et al.

Serial No.: 09/831,879

Art Unit:

To Be Assigned Filed: May 22, 2001 Examiner:

For: Adhesive Gel Compositions For Iontophoresis

And Devices Therefor

REQUEST FOR CORRECTED FILING RECEIPT

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Applicants' counsel is in receipt of the PTO Filing Receipt for the above identified pending patent application, a copy of which is attached hereto. Upon verifying the accuracy of the data presented on the Filing Receipt it was noted that there are errors in the title for this invention which were introduced by the Patent As evidence by the attached copy of the Transmittal, Office. Declaration and Power of Attorney, and first page of the original specification which contains the title, the title should be "Adhesive Gel Compositions For Iontophoresis And Devices Therefor" rather than "Pressure-Sensitive Adhesive Gel Composition For Iontophoresis And Apparatus Therefor".

It is respectfully requested that the Patent Office records be corrected to reflect the correct title and that the undersigned be provided with a corrected Filing Receipt.

Respectfully submitted,

TOWNSEND & BANTA


rule 7. 1 owners

Donald E. Townsend, Jr

Reg. No. 43,198

July 12, 2001 Date:

TOWNSEND & BANTA Suite 500 1225 Eye Street, N.W. 20005 Washington, D.C. (202) 682-4727



COMMISSIONER FOR WASHINGTON, D.C. 2023
WASHINGTON, D.C. 2023
WWW.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY, DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS	
09/831,879	05/22/2001	1615	860	MUR-026- USA-		13	2	

CONFIRMATION NO. 8324

FILING RECEIPT

QC000000000250680

Law Offices of Townsend & Banta Suite 500 1225 Eye Street NW Washington, DC 20005

Date Mailed: 07/02/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Cust mer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If y u received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kazuya Katagai, Tsukuba-shi, JAPAN; Hirotoshi Adachi, Tsukuba-shi, JAPAN; Kazutaka Inoue, Tsukuba-shi, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/06241 11/10/1999

Foreign Applications

JAPAN 10/335602 11/26/1998

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

Title

Pressure-sensitive adhesive gel composition for iontophor sis and apparatus therefor

Preliminary Class

MAR 13 2002 TC 3700 MAIL ROOM



GRANTED

TOTORINA FILING WITH The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FORE LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls. Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (i)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined)
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" your on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, DC 20231

424

Data entry by : ORDENEZ, MARTA

Team : OIPE

Date: 07/02/2001

TRA	ANSMITTAL LAT	110K 020-03A-PC1							
· . I	DESIGNATED	EC IED OFFICE (DO/EO/IJS)	J.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
		ILING UNDER 35 U.S.C. 371	U.S. AFFLICATION NO. (If known, see 37 CFR 1.5)						
	IONAL APPLICATION NO.	INTERNATIONAL FILING DATE	777.77						
	JP99/06241	November 10, 1999	PRIORITY DATE CLAIMED						
		ive Gel Compositions For Iont	November 26, 1998						
		ces Therefor	_ Ai						
APPLICANT(S) FOR DO/EO/US									
Razuya Katadai, Hilotoshi Adachi and Kazutaka Inoue									
	plicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X T	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2 T	his is a SECOND or SUBSEC	QUENT submission of items concerning a filing under 3	95 U.S.C. 371.						
	1-0								
	PADEMA								
	a. Listatched hereto (required only if not communicated by the International Bureau).								
b. c.	r - 1	cated by the International Bureau.							
	n English language terrale	he application was filed in the United States Received	ving Office (RO/US).						
		tion of the International Application as filed (35 U							
		of the International Application under PCT Article							
a.		(required only if not communicated by the Interna	itional Bureau).						
b.	9 - 3	icated by the International Bureau.							
c.	have not been made	e; however, the time limit for making such amendn	nents has NOT expired.						
d.	X have not been made	and will not be made.							
8. L. A.	n English language translat	ion of the amendments to the claims under PCT A	Article 19 (35 U.S.C. 371(c)(3)).						
		e inventor(s) (35 U.S.C. 371(c)(4)).	(
	CT Article 36 (35 U.S.C. 37	ion of the annexes to the International Preliminary 71(c)(5)).	Examination Report under						
		ent(s) or information included:							
11 An	Information Disclosure S	tatement under 37 CFR 1.97 and 1.98.							
2. 🛭 An	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
— 111 miles prominently differentially differential									
LJ AS	A SECOND or SUBSEQUENT preliminary amendment.								
4. 🔲 A s	A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. A change of power of attorney and/or address letter. Other items or information: Claim For Priority English translations of an Amendment filed								
· 🗀 🙃	A substitute specification.								
5. 🔲 A d	change of power of attorney	y and/or address letter.	17R / FEC						
_	A CH								
6. kul Otł	ner items or information:	Claim For Priority	200						
		English translations of an Ar	mendment filed						
		June 7, 2000 under Article 3	4 of substituted pages						
	•	for original page 61 and Amer	ndment filed October						
		5, 2000 of substituted pages	for the original						
		pages 5, 35 and 60.							



DHEST EVE GEL COMPOSITIONS FOR IONTOPHORESIS AND DEVICES THEREFOR

TECHNICAL FIELD

The present invention relates an adhesive gel composition for an iontophoresis which is applied transdermally or transmucosally and which allows achasic drug to be delivered into an in vivo site utilizing an electr driving force and a device therefore.

BACKGROUND OF THE INVENTION

An iontophoresis is a transdermal and transmucosal absorption-enhancing system utilizing an electric driving force, and its principal is an enhancement of a skin barrier penetration of a drug molecule based on a force by which a positively-charged molecule is moved from a cathode to an anode and a negatively-charged molecule is moved from the anode to the cathode in an electric field generated between the cathode and the anode mainly by energization [See Journal of Controlled Release, Vol.18, 1992, pp.213 to 220; Advanced Drug Delivery Review, Vol.9, 1992, p.119; Pharmaceutical Research, Vol.3, 1986, pp.318 to 326].

As adhesive compositions which have been mployed in a 25 transdermal therapeutic system (TTS), many ones containing

5

10

15

20